SCNI

Scinai Immunotherapeutics Ltd. Sponsored ADR · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Other
Website cinai.com
Employees(FY) 33
ISIN US09073Q2049

Performance

-1.14%

1W

-4.28%

1M

-4.28%

3M

-29.7%

6M

-24.44%

YTD

-76.81%

1Y

Profile

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Advanced Technical Analysis

Technical Analysis of SCNI 2024-05-03

Overview:

In analyzing the technical indicators for SCNI over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key factors, we aim to offer valuable insights and predictions for the upcoming days.

Trend Indicators...

See more ...

Recent News & Updates

2024-05-05 21:21
Scinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and Appeal(Prnewswire)
2024-04-09 19:00
Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schn of UMG(Prnewswire)
2024-04-07 19:00
Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services(Prnewswire)
2024-03-11 20:00
Scinai leadership to attend BIO-Europe Spring 2024(Prnewswire)
2024-02-28 19:45
Scinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024(Prnewswire)
2024-02-12 18:00
Scinai Welcomes Liat Halpert as Head of Business Development and Sales(Prnewswire)
2024-01-24 21:26
Scinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Grlich on Louis-Jeantet Prize(Prnewswire)
2024-01-04 03:01
Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds(Prnewswire)
2024-01-03 17:15
Scinai Immunotherapeutics CEO Issues Letter to Shareholders(Prnewswire)
2023-12-28 20:21
Scinai Immunotherapeutics Announces Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds(Prnewswire)
2023-12-26 18:15
Scinai (NASDAQ: SCNI) to Host Analyst and Investor Webinar on January 9(Prnewswire)
2023-12-19 19:05
Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors(Globenewswire)
2023-12-11 18:26
Scinai Announces Promising Results in a Psoriatic Human Skin Model(Prnewswire)
2023-12-10 19:11
Study published in Antiviral Research supports promise of Scinai Immunotherapeutics' coronavirus NanoAb as aerosolized prophylactic and therapeutic drug(Prnewswire)
2023-11-28 20:25
European Investment Bank (EIB) extends maturity of its finance facility with Scinai Immunotherapeutics from 2027 to 2031(Prnewswire)
2023-11-19 18:30
Scinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders' Equity Rule(Prnewswire)
2023-11-05 18:30
Scinai Immunotherapeutics Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting its New CDMO Business Unit(Globenewswire)
2023-11-03 04:30
Scinai Immunotherapeutics Provides Update Regarding Nasdaq Compliance(Globenewswire)
2023-10-30 21:00
European Investment Bank (EIB) considering extending maturity of its financial facility contract with Scinai Immunotherapeutics in light of Scinai's recent strategic pivot(Globenewswire)
2023-10-30 20:23
Scinai Reports Third Quarter 2023 Financial Results and Provides Business Update(Globenewswire)
2023-10-29 19:00
Scinai Immunotherapeutics to Attend BIO-Europe Munich 2023(Globenewswire)
2023-10-03 19:30
Scinai Immunotherapeutics to Showcase its end-to-end cGMP Biologics CDMO Services at CPHI Barcelona 2023(Globenewswire)
2023-09-19 04:05
Scinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offering(Yahoo Finance)
2023-09-14 21:01
Scinai Immunotherapeutics Announces $1.33 Million Registered Direct Offering(Yahoo Finance)
2023-09-13 04:13
Scinai Immunotherapeutics Innovative Plaque Psoriasis Treatment Shows Encouraging Preclinical Results(Yahoo Finance)
2023-09-10 19:30
Scinai Immunotherapeutics Ltd. to participate this week in H.C. Wainwright 25th Annual Global Investment Conference in New York and LSX USA Congress 2023 in Boston(Yahoo Finance)
2023-09-05 18:00
BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics(Yahoo Finance)
2023-08-10 21:00
BiondVax Reports Second Quarter Financial Results and Provides Business Update(Yahoo Finance)
2023-08-01 04:01
Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules(Yahoo Finance)
2023-07-10 20:17
IBN Announces Latest Episode of The Bell2Bell Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd.(Yahoo Finance)

Page 1 of 4

previousnext